GS
ASMB icon

Gilead Sciences’s Assembly Biosciences ASMB Stock Holding History

Gilead Sciences’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$137M Buy
4,977,089
+471,698
+10% +$12.8M 8.3% 3
2026
Q1 		$125M Hold
4,505,391
– – 5.9% 4
2025
Q4 		$153M Hold
4,505,391
– – 7.92% 4
2025
Q3 		$115M Buy
4,505,391
+2,295,920
+104% +$50.4M 6.44% 4
2025
Q2 		$40M Hold
2,209,471
– – 3.13% 4
2025
Q1 		$21.1M Hold
2,209,471
– – 1.79% 4
2024
Q4 		$34.9M Buy
+2,209,471
New +$35.6M 2.25% 4

Other funds holding ASMB

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $606M AUM

Gilead Sciences's ASMB Position: Q2 2026 in Review

Gilead Sciences increased its Assembly Biosciences (ASMB) stake by 10% in Q2 2026, buying an estimated $12.8M and bringing the position to 4,977,089 shares worth $137M. The position accounts for 8.3% of the portfolio, ranked #3.

Gilead Sciences first reported a position in ASMB in Q4 2024 and has held it in 7 quarters since. The position peaked at $153M in Q4 2025. 92 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Gilead Sciences held 4,977,089 shares of Assembly Biosciences worth $137M as of Q2 2026.
  • Gilead Sciences bought 471,698 Assembly Biosciences shares in Q2 2026, an estimated $12.8M.
  • Assembly Biosciences made up 8.3% of Gilead Sciences's portfolio in Q2 2026, its #3 holding.
  • Gilead Sciences first reported a position in Assembly Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Gilead Sciences's Assembly Biosciences position peaked at $153M in Q4 2025.
  • 92 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.